aprepitant "sandoz" 125 mg kapsler, hårde
sandoz a/s - aprepitant - kapsler, hårde - 125 mg
aprepitant "stada" 125 mg kapsler, hårde
stada arzneimittel ag - aprepitant - kapsler, hårde - 125 mg
endoxan 50 mg overtrukne tabletter
paranova danmark a/s - cyclophosphamid, vandfrit - overtrukne tabletter - 50 mg
atanto 80 mg kapsler, hårde
pharmathen s.a. - aprepitant - kapsler, hårde - 80 mg
cyclophosphamid carefarm 1 g pulver til injektionsvæske, opløsning
orifarm a/s - cyclophosphamid, vandfrit - pulver til injektionsvæske, opløsning - 1 g
cyclophosphamid "2care4" 500 mg pulver til injektionsvæske, opløsning
2care4 aps - cyclophosphamid, vandfrit - pulver til injektionsvæske, opløsning - 500 mg
fludarabinphosphat "actavis" 50 mg pulver til injektions-/infusionsvæske, opløsning
actavis group ptc ehf. - fludarabinphosphat - pulver til injektions-/infusionsvæske, opløsning - 50 mg
flurablastin 50 mg/ml injektionsvæske, opløsning
pfizer aps - fluoruracil - injektionsvæske, opløsning - 50 mg/ml
fludarabinphosphat "teva" 25 mg/ml koncentrat til injektions-/infusionsvæske, opløsning
teva b.v. - fludarabinphosphat - koncentrat til injektions-/infusionsvæske, opløsning - 25 mg/ml
blincyto
amgen europe b.v. - blinatumomab - forløbercellelimfoblastisk leukæmi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.